Cristina Csimma is a seasoned biopharmaceutical CEO with fund raising, company building and drug development expertise in the biopharmaceutical industry, venture capital and academic settings. Her experience encompasses global development in multiple therapeutic areas, translational through registration clinical studies, rare diseases, and integration of biomarkers and novel technologies into development. She was the founding CEO of Cydan Development, Inc., a privately held company focused on advancing the translation of therapeutics for orphan diseases and was previously Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures LLC, held roles in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute.
She serves on the Board of Directors of Vtesse Inc. and Juniper Pharma; the Muscular Dystrophy Association Scientific Development Advisory Committee; the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network; the External Oversight Committee of NIH Blueprint Neurotherapeutics Network, the Rockefeller University Robertson Therapeutic Development Fund Review Committee, the Scientific Advisory Board of CureDuchenne, the Business Advisory Board of Akashi Therapeutics, the TREAT-NMD Advisory Committee for Therapeutics (TACT), Founding Chair (2009-2012) and Northeastern University’s Health Sciences Entrepreneurs steering committee.
Dr. Csimma received her Bachelor of Science and Doctor of Pharmacy degrees from Massachusetts College of Pharmacy, and a Master of Health Professions from Northeastern University.